Indivior Earnings Call Highlights SUBLOCADE-Fueled Momentum

Indivior plc ((INDV)) has held its Q1 earnings call. Read on for the main highlights of the call.

Indivior’s latest earnings call struck an upbeat tone, with management leaning hard into strong SUBLOCADE momentum and sharply improved profitability. Executives acknowledged setbacks in early-stage research and looming gross-to-net headwinds, but argued that disciplined cost control, a stronger balance sheet, and upgraded guidance more than offset these concerns for investors focused on near- to medium-term performance.

Robust Top-Line Expansion

Indivior delivered a solid revenue beat in Q1 2026, posting total net revenue of $317 million, up 19% versus the prior year. Management framed this as evidence that the company is executing well commercially, even as broader markets for addiction treatment remain competitive and reimbursement dynamics grow more complex.

SUBLOCADE Drives Revenue Acceleration

The growth engine remains SUBLOCADE, whose net revenue surged 32% year over year to $232 million, with U.S. sales up 33% to $218 million. That performance was underpinned by 20% growth in dispense units and a favorable price and mix backdrop, reinforcing SUBLOCADE’s central role in the investment story and in Indivior’s top-line trajectory.

Patient Adoption and Prescriber Engagement Surge

Demand indicators around SUBLOCADE continued to strengthen, with record new patient starts of roughly 31,800 in Q1, a 29% increase year over year. Since launch, more than 500,000 U.S. patients have received SUBLOCADE, and active prescribers grew 19%, with a 20% rise in clinicians treating five or more patients, pointing to deeper penetration and stickier usage patterns.

Record Profitability and Margin Expansion

Profitability inflected sharply, as adjusted EBITDA hit a record $164 million, up 112% year over year, translating into a 23 percentage point improvement in margins. The company also lifted its 2026 adjusted EBITDA guidance to a range of $620 million to $660 million, implying a midpoint margin near 51% and underscoring the operating leverage embedded in the SUBLOCADE growth story.

Guidance Raised on SUBLOCADE Strength

Reflecting this momentum, Indivior raised its 2026 financial outlook, now projecting total net revenue between $1.215 billion and $1.285 billion, with a midpoint modestly above 2025. SUBLOCADE’s 2026 revenue is now guided to $950 million to $990 million, implying about 13% growth and mid-teens dispense unit increases after a more subdued 2025 volume cadence.

Operating Efficiency and Leaner Cost Base

The company continued to trim costs, reporting non-GAAP operating expenses of $116 million in Q1, down 21% from a year ago. Management credited headcount reductions, R&D and medical affairs restructuring, and footprint consolidation, arguing that Indivior is now structurally leaner and better positioned to convert incremental revenue into earnings and cash.

Balance Sheet Repair and Capital Returns

Indivior took notable steps to streamline its capital structure, issuing $500 million in senior convertible notes mainly to retire a $333 million term loan and slash its interest rate to 0.625% from 9.5%. The company also repurchased $125 million of stock, about four million shares, and still has roughly $275 million of buyback capacity, while ending Q1 with $201 million in gross cash and projecting leverage near 0.8 times in 2026.

Commercial Execution and Marketing Impact

Management highlighted early wins from its “Move Forward in Recovery” direct-to-consumer campaign, which is generating more than 1,200 new CRM enrollments per month and over 30,000 provider searches in the quarter. Enhanced specialty pharmacy agreements and improved dispense yields are also being rolled out, reinforcing the commercial infrastructure supporting SUBLOCADE adoption.

INDV-6001 Shelved After Strategic Review

On the R&D side, Indivior decided not to advance INDV-6001 into Phase III, returning certain rights to Alar Pharmaceuticals. The company pointed to challenges such as manufacturing scalability, limited differentiation for payers and prescribers, and a more complex induction protocol versus SUBLOCADE, reinforcing its focus on projects with clearer commercial upside.

INDV-2000 Misses Endpoint in Phase II

INDV-2000 also stumbled, failing to hit its primary endpoint across the full dose range in Phase II for opioid use disorder, with 400 mg underperforming and placebo responses running unexpectedly high. Although an exploratory signal emerged at 200 mg, Indivior will not continue OUD development internally and instead will look for external partners for potential further work.

Gross-to-Net Headwinds on the Horizon

Despite a $14 million gross-to-net benefit from prior-year adjustments in Q1, management warned that such adjustments are likely to become a headwind through the rest of 2026. They acknowledged uncertainty around the timing and magnitude of future gross-to-net movements, signaling that reported revenue growth may be choppier than underlying demand trends.

R&D Organization Reset and Cost Impact

The decisions to halt internal development of INDV-6001 and INDV-2000 will significantly reshape the R&D organization, even though management emphasized the quality of the underlying science. These moves are already contributing to lower operating expenses, aligning the cost base with a more focused pipeline and freeing up capital for other strategic uses.

Revenue Concentration and Competitive Risks

Investors were reminded that near-term growth remains highly concentrated in SUBLOCADE, with total 2026 revenue only modestly higher than 2025 at the midpoint despite strong franchise gains. Management also flagged competitive and intellectual property risks, including potential generic entries, even as they pointed to Orange Book-listed patents extending into the 2030s to support the brand’s durability.

Upgraded Outlook and Financial Trajectory

Looking ahead, Indivior’s raised guidance calls for 2026 adjusted EBITDA of $620 million to $660 million, operating expenses of $430 million to $450 million, and around $340 million in operating cash flow. The company expects gross margins in the mid-80s and believes its streamlined balance sheet and capital allocation plans leave it well positioned to fund growth while continuing shareholder returns.

Indivior’s earnings call painted a picture of a company riding powerful SUBLOCADE momentum and translating it into higher margins, stronger cash flow, and meaningful capital returns. While R&D setbacks, gross-to-net noise, and concentration risk temper the narrative, management’s upgraded guidance and balance sheet progress suggest the near-term investment case remains firmly intact for investors betting on sustained SUBLOCADE dominance.